Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Rumi, Elisa  [Clear All Filters]
2019
Marchetti M, Ghirardi A, Masciulli A, Carobbio A, Palandri F, Vianelli N, Rossi E, Betti S, Di Veroli A, Iurlo A, et al. Second cancers in MPN: survival analysis from an international study. Am J Hematol. 2019.
Maffioli M, Giorgino T, Mora B, Iurlo A, Elli E, Finazzi MChiara, Caramella M, Rumi E, Carraro MCristina, Polverelli N, et al. Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients. Blood Adv. 2019;3(21):3196-3200.
2021
Alvarez-Larran A, Sant'Antonio E, Harrison C, Kiladjian J-J, Griesshammer M, Mesa R, Ianotto JChristophe, Palandri F, Hernández-Boluda JCarlos, Birgegård G, et al. Unmet clinical needs in the management of CALR-mutated essential thrombocythaemia: a consensus-based proposal from the European LeukemiaNet. Lancet Haematol. 2021;8(9):e658-e665.
2022
Feenstra JDMilosevi, Jäger R, Schischlik F, Ivanov D, Eisenwort G, Rumi E, Schuster M, Gisslinger B, Machherndl-Spandl S, Bettelheim P, et al. PD-L1 Overexpression Correlates with JAK2-V617F Mutational Burden and Is Associated with 9p Uniparental Disomy in Myeloproliferative Neoplasms. Am J Hematol. 2022.
2023
Mora B, Maffioli M, Rumi E, Guglielmelli P, Caramella M, Kuykendall A, Palandri F, Iurlo A, De Stefano V, Kiladjian J-J, et al. Incidence of blast phase in myelofibrosis according to anemia severity. EJHaem. 2023;4(3):679-689.